Fig. 5: SRC knockout reduced GC cells sensitivity to vortioxetine hydrobromide. | Oncogenesis

Fig. 5: SRC knockout reduced GC cells sensitivity to vortioxetine hydrobromide.

From: Vortioxetine hydrobromide inhibits the growth of gastric cancer cells in vivo and in vitro by targeting JAK2 and SRC

Fig. 5

A CRISPR/Cas9 system was used to knockout SRC in HGC27 and AGS cells. Knockout efficiency in GC cells were assessed by Western blotting. B Cell viability after SRC knockout was assessed by MTT (96 h after seeding cells) assay. C Colony numbers of SRC knockout cells were measured. D The protein levels of p-STAT3 Y705 and STAT3 in SRC knockout cells by Western blotting. E The inhibitory effect of vortioxetine hydrobromide on SRC knockout cells was detected by proliferation assay after 96 h. Cell viability was evaluated by MTT assay and normalized to that of the control. F SRC knockout cells were plated into 6-well plates and treated with various concentration of vortioxetine hydrobromide (0, 0.5, 1, 2, 4 μM) for 10 days, followed by crystal violet staining to monitor colony formation. Mean ± S.D. (n = 3) (*p < 0.05, **p < 0.01, ***p < 0.001).

Back to article page